Treatment of hypertrophic cardiomyopathy with beta blockers or calcium antagonists

Author(s):  
M. Kaltenbach ◽  
R. Hopf
2019 ◽  
Vol 15 (1) ◽  
Author(s):  
Ryohei Suzuki ◽  
Yohei Mochizuki ◽  
Yunosuke Yuchi ◽  
Yuyo Yasumura ◽  
Takahiro Saito ◽  
...  

Abstract Background Inconsistency of treatment response in cats with obstructive hypertrophic cardiomyopathy is well recognized. We hypothesized that the difference in response to beta-blockers may be caused by myocardial functional abnormalities. This study was designed to compare myocardial function in cats with obstructive hypertrophic cardiomyopathy with and without response to beta-blockers. Twenty-one, client-owned, hypertrophic cardiomyopathy cats treated with carvedilol were analyzed. After carvedilol treatment, cats with decreased left ventricular outflow tract velocity were categorized as responders (n = 10); those exhibiting no response (no decrease in the left ventricular outflow tract velocity) were categorized as non-responders (n = 11). The cats were examined using layer-specific assessment of the myocardial function (whole, endocardial, and epicardial layers) longitudinally and circumferentially by two-dimensional speckle-tracking echocardiography, before and after carvedilol treatment. Results The non-responder cats had a significantly higher age, end-diastolic left ventricular posterior-wall thickness, peak velocity of left ventricular outflow tract, and dose of carvedilol than the responders (p = 0.04, p < 0.01, p < 0.01, and p < 0.01, respectively). The circumferential strain in the epicardial layer was lower and circumferential endocardial to epicardial strain ratio was higher in non-responders than responders (p < 0.001 and p = 0.006). According to the multivariate analysis, circumferential strain in the epicardial layer was the only independent correlate of treatment response with carvedilol. Conclusions Myocardial function, assessed by two-dimensional speckle-tracking echocardiography, differed in cats with hypertrophic cardiomyopathy with and without response to beta-blockers. The determination of layer-specific myocardial function may facilitate detailed pathophysiologic assessment and treatment response in cats with hypertrophic cardiomyopathy.


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M E A M Van Kleef ◽  
E M Van Maarseveen ◽  
F L J Visseren ◽  
P J Blankestijn ◽  
M L Bots ◽  
...  

Abstract Background/Introduction Antihypertensive medication screening by qualitative high performance chromatography-tandem mass spectrometry (LC-MS/MS) has recently become available to detect non-adherence to antihypertensive treatment. Because the result of this test is dichotomous (the drug is detected or not), it may incorrectly classify patients who take their medications infrequently. Therefore, a quantitative screening method has been developed to improve detection of non-adherence. Purpose The aim of this study was to determine the prevalence of medication non-adherence assessed by quantitative LC-MS/MS in referred hypertensive patients. In addition, we determined to what extent clinical characteristics, prescribed medication and self-reported perspectives, were associated with medication non-adherence assessed by quantitative LC-MS/MS. Methods In this cross-sectional study we included 197 newly referred hypertensive patients (mean age 56±14 years, 101 women, mean 24-hour ambulatory blood pressure 143/85±21/12 mmHg) prescribed at least one antihypertensive drug. Medication adherence was assessed by quantitative LC-MS/MS in plasma. The concentration of each prescribed drug (or its metabolite) was measured and divided by the literature-based population trough concentration, to get the concentration ratio (CR). If the CR of at least one of the prescribed drugs was ≤0.3 the patient was categorized as non-adherent: completely non-adherent if all were ≤0.3, partially non-adherent if not all were ≤0.3. Logistic regression analysis was performed to determine the association between clinical characteristics, prescribed medication and self-reported compliance (Hill & Bone), relational empathy (CARE) and beliefs about medicines (BMQ), and medication non-adherence. Results 29% was classified as partially non-adherent and 10% as completely non-adherent. Non-adherence to calcium antagonists (30%) and beta blockers (24%) prevailed non-adherence to other antihypertensive medication classes (6–11%). The odds of non-adherence were higher in patients with apparent resistant hypertension and increased with the number of antihypertensive medication types, tablets and daily defined dose prescribed (Figure 1). Combination pills were inversely associated with non-adherence. Self-reported measures were not associated. Older age was negatively associated with non-adherence to RAS inhibitors (OR 0.60, 95% CI 0.36–0.96) and beta blockers (OR 0.50, 95% CI 0.30–0.77). Figure 1 Conclusions Quantitative screening by LC-MS/MS in plasma shows a high prevalence of non-adherence in referred hypertensive patients, particularly for calcium antagonists and beta blockers. The observation that clinical characteristics and self-reported perspectives about medical treatment were not associated with non-adherence, supports the use of quantitative LC-MS/MS to detect non-adherence to antihypertensive medication in daily practice.


JAMA ◽  
1980 ◽  
Vol 243 (14) ◽  
pp. 1464
Author(s):  
Samuel Vaisrug

1991 ◽  
Vol 17 (3) ◽  
pp. 357-364 ◽  
Author(s):  
Stig Haunsø ◽  
Per Sejrsen ◽  
Jesper Hastrup Svendsen

Sign in / Sign up

Export Citation Format

Share Document